



ASX Announcement

27 January 2022

## Atomo receives approval for its COVID-19 antigen test in NZ

**SYDNEY, Australia, Thursday 27 January 2022** - Atomo Diagnostics Limited (ASX:AT1) (**Atomo**) is pleased to advise that the Atomo COVID-19 Antigen Test<sup>1</sup> (Nasal, Nasopharyngeal, or Oropharyngeal swab) has been authorised by the New Zealand Ministry of Health under the New Zealand COVID-19 Public Health Response 2020 (Point of Care) Order (**the Order**).

The authorisation covers professional or self-test use and means authorised persons or classes of persons such as NZ District Health Board hospitals, Government agencies, the healthcare workforce, New Zealand-based businesses and pharmacies are all permitted to supply, distribute, and sell the COVID-19 Antigen Test in New Zealand to other authorised persons or classes of persons, and to also use the Test.

Atomo announced on 5 October 2021 that it had renegotiated its supply agreement with US manufacturer Access Bio providing the right, but not the obligation, for Atomo to purchase at a fixed price per unit up to 20 million COVID-19 rapid antigen tests (Atomo branded) during CY22 for sale in Australia and New Zealand.

Atomo's Managing Director John Kelly said, "We are excited the Atomo antigen test has received approval for use in New Zealand and we have now commenced commercial discussions related to supply of the product to the New Zealand market."

For more information, please contact:

Jane Lowe  
IR Department  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
Phone: +61 411 117 774

John Kelly  
Atomo Diagnostics  
[john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
Phone: +61 401 922 279

---

<sup>1</sup> COVID-19 rapid testing detects SARS-COV-2, the virus that causes COVID-19.



*This announcement was authorised by the Managing Director.*

### **About Atomo**

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com).

### **Forward looking statements**

This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may”, and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Atomo or its Directors and management, and could cause Atomo's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements